Literature DB >> 7492099

In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii.

M E Fichera1, M K Bhopale, D S Roos.   

Abstract

In order to characterize the delayed effect of clindamycin and macrolide antibiotics against Toxoplasma gondii tachyzoites (E. R. Pfefferkorn and S. E. Borotz, Antimicrob. Agents Chemother. 38:31-37, 1994), we have carefully examined the replication of parasites as a function of time after drug addition. Intracellular tachyzoites treated with up to 20 microM clindamycin (> 1,000 times the 50% inhibitory concentration) exhibit doubling times indistinguishable from those of controls (approximately 7 h). Drug-treated parasites emerge from infected cells and establish parasitophorous vacuoles inside new host cells as efficiently as untreated controls, but replication within the second vacuole is dramatically slowed. Growth inhibition in the second vacuole does not require continued presence of drug, but it is dependent solely on the concentration and duration of drug treatment in the first (previous) vacuole. The susceptibility of intracellular parasites to nanomolar concentrations of clindamycin contrasts with that of extracellular tachyzoites, which are completely resistant to treatment, even through several cycles of subsequent intracellular replication. This peculiar phenotype, in which drug effects are observed only in the second infectious cycle, also characterizes azithromycin and chloramphenicol treatment, but not treatment with cycloheximide, tetracycline, or anisomycin. These findings provide new insights into the mode of clindamycin and macrolide action against T. gondii, although the relevant target for their action remains unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492099      PMCID: PMC162776          DOI: 10.1128/AAC.39.7.1530

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA.

Authors:  S Douthwaite
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

2.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

3.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

4.  Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis.

Authors:  M Tenant-Flowers; M J Boyle; D Carey; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

5.  Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.

Authors:  C J Beckers; D S Roos; R G Donald; B J Luft; J C Schwab; Y Cao; K A Joiner
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

6.  Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of Toxoplasma gondii.

Authors:  D Bermudes; K R Peck; M A Afifi; C J Beckers; K A Joiner
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

Review 7.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

Review 8.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin.

Authors:  E R Pfefferkorn; S E Borotz
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more
  59 in total

1.  Daughter cell assembly in the protozoan parasite Toxoplasma gondii.

Authors:  Ke Hu; Tara Mann; Boris Striepen; Con J M Beckers; David S Roos; John M Murray
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

2.  High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein.

Authors:  Marc-Jan Gubbels; Catherine Li; Boris Striepen
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Dynamics of Toxoplasma gondii differentiation.

Authors:  Florence Dzierszinski; Manami Nishi; Lillian Ouko; David S Roos
Journal:  Eukaryot Cell       Date:  2004-08

4.  Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants.

Authors:  Gabriella M Fernandes-Cunha; Cíntia M F Rezende; Wagner N Mussel; Gisele R da Silva; Elionai C de L Gomes; Maria I Yoshida; Sílvia L Fialho; Alfredo M Goes; Dawison A Gomes; Ricardo W de Almeida Vitor; Armando Silva-Cunha
Journal:  J Mater Sci Mater Med       Date:  2015-12-16       Impact factor: 3.896

5.  Chemistry and biology of macrolide antiparasitic agents.

Authors:  Younjoo Lee; Jun Yong Choi; Hong Fu; Colin Harvey; Sandeep Ravindran; William R Roush; John C Boothroyd; Chaitan Khosla
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

6.  Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast.

Authors:  Erica L Dahl; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

7.  Double-stranded RNA specific to adenosine kinase and hypoxanthine-xanthine-guanine-phosphoribosyltransferase retards growth of Toxoplasma gondii.

Authors:  Li Yu; Yu-Feng Gao; Xia Li; Zeng-Pei Qiao; Ji-Long Shen
Journal:  Parasitol Res       Date:  2008-10-03       Impact factor: 2.289

8.  Toxoplasma gondii nucleus coding apicoplast protein ACP synthesis and trafficking in delayed death.

Authors:  Liang Wu; Jin Shen; Yupei Zhou; Xiao Wang; Lamei Wu; Xugan Jiang; Shengxia Chen
Journal:  Parasitol Res       Date:  2015-01-07       Impact factor: 2.289

9.  A plastid segregation defect in the protozoan parasite Toxoplasma gondii.

Authors:  C Y He; M K Shaw; C H Pletcher; B Striepen; L G Tilney; D S Roos
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

Review 10.  'FAS't inhibition of malaria.

Authors:  Avadhesha Surolia; T N C Ramya; V Ramya; Namita Surolia
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.